Anti‐diabetic drugs and sarcopenia: emerging links, mechanistic insights, and clinical implications
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Sarcopenia, characterized by loss of skeletal muscle mass, quality, and strength, has become a common hallmark of ageing and many chronic diseases. Diabetes mellitus patients have a higher prevalence of sarcopenia, which greatly aggravates the metabolic disturbance and compromises treatment response. Preclinical and clinical studies have shown differential impacts of anti‐diabetic drugs on skeletal muscle mass, strength, and performance, highlighting the importance of rational therapeutic regimen from the perspective of sarcopenia risk. In this review, we provide an update on the regulation of muscle mass and quality by major anti‐diabetic drugs, focusing primarily on emerging data from clinical studies. We also discuss the underlying mechanisms and clinical implications for optimal selection of anti‐diabetic drugs to reduce the risk of sarcopenia. In view of the lifelong use of anti‐diabetic drugs, we propose that a better understanding of the sarcopenia risk and interventional strategies is worthy of attention in future studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bolinder, J., Ljunggren, Ö., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A. M., Sugg, J., & Parikh, S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2260 · Cited by 867 · cited 1×
“Some other studies have also shown that the use of SGLT2 inhibitors in T2DM patients reduces FM by two-thirds and lean mass by one-third.(78,79) Typically, both ipragliflozin and canagliflozin reduce the weight of FM and lean mass.”
ResultMusi, N., Hirshman, M. F., Nygren, J., Svanfeldt, M., Bavenholm, P., Rooyackers, O., Zhou, G., Williamson, J. M., Ljunqvist, O., Efendic, S., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.7.2074 · Cited by 806
Excessive Loss of Skeletal Muscle Mass in Older Adults With Type 2 Diabetes
Park, S. W., Goodpaster, B. H., Lee, J. S., Kuller, L. H., Boudreau, R., de Rekeneire, N., Harris, T. B., Kritchevsky, S., Tylavsky, F. A., Nevitt, M., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0264 · Cited by 778 · cited 2×
“Older people with diabetes are twice more likely to develop sarcopenia than those without diabetes.(6,7) The strength and resistance of skeletal muscle decreased significantly in type 2 diabetes mellitus (T2DM) patients.”
BackgroundAccelerated Loss of Skeletal Muscle Strength in Older Adults With Type 2 Diabetes
Park, S. W., Goodpaster, B. H., Strotmeyer, E. S., Kuller, L. H., Broudeau, R., Kammerer, C., de Rekeneire, N., Harris, T. B., Schwartz, A. V., Tylavsky, F. A., et al. (2007) · Diabetes Care · doi:10.2337/dc06-2537 · Cited by 766 · cited 1×
“Older people with diabetes are twice more likely to develop sarcopenia than those without diabetes.(6,7) The strength and resistance of skeletal muscle decreased significantly in type 2 diabetes mellitus (T2DM) patients.”
BackgroundDecreased Muscle Strength and Quality in Older Adults With Type 2 Diabetes
Park, S. W., Goodpaster, B. H., Strotmeyer, E. S., de Rekeneire, N., Harris, T. B., Schwartz, A. V., Tylavsky, F. A., & Newman, A. B. (2006) · Diabetes · doi:10.2337/db05-1183 · Cited by 751 · cited 1×
“The strength and resistance of skeletal muscle decreased significantly in type 2 diabetes mellitus (T2DM) patients.(8,9) Poor glycaemic control in patients with diabetes could further lead to low muscle mass.”
BackgroundUnderstanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus
Foretz, M., Guigas, B., & Viollet, B. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0242-2 · Cited by 686 · cited 1×
“liver, intestine, adipose tissue, as well as the muscle.(36) The glycaemic decrease during metformin treatment is more often accompanied by weight loss, and many studies have consistently associated long-term metformin use with decreased FM.”
BackgroundFunction and mechanisms of enteroendocrine cells and gut hormones in metabolism
Gribble, F. M., & Reimann, F. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0168-8 · Cited by 670
Sarcopenic obesity: a critical appraisal of the current evidence
Prado, C. M. M., Wells, J. C. K., Smith, S. R., Stephan, B. C. M., & Siervo, M. (2012) · Clinical Nutrition · doi:10.1016/j.clnu.2012.06.010 · Cited by 589
Prevalence and Determinant Factors of Sarcopenia in Patients With Type 2 Diabetes
Kim, T. N., Park, M. S., Yang, S. J., Yoo, H. J., Kang, H. J., Song, W., Seo, J. A., Kim, S. G., Kim, N. H., Baik, S. H., et al. (2010) · Diabetes Care · doi:10.2337/dc09-2310 · Cited by 585
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Brown, E., Heerspink, H. J. L., Cuthbertson, D. J., & Wilding, J. P. H. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00536-5 · Cited by 581
Cited by
Gorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., Castro, A., Cebrián-Cuenca, A., de Torres-Sánchez, A., García-de-Lucas, M. D., Núñez, J., Obaya, J. C., Soler, M. J., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010145 · Cited by 358
Higher Risk of Sarcopenia in Older Adults with Type 2 Diabetes: NHANES 1999–2018
Dai, S., Shu, D., Meng, F., Chen, Y., Wang, J., Liu, X., Xiao, X., Guo, W., & Chen, F. (2023) · Obesity Facts · doi:10.1159/000530241 · Cited by 63
Giannakogeorgou, A., & Roden, M. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17848 · Cited by 30
Scheen, A. J. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101681 · Cited by 30
Metadata
- Authors
- Zhang, X., Zhao, Y., Chen, S., & Shao, H.
- Venue
- Journal of Cachexia, Sarcopenia and Muscle
- Publisher
- Wiley
- Published
- 2021-10-21
- Volume
- 12
- Issue
- 6
- Pages
- 1368-1379
- ISSN
- 2190-5991 (ISSN-L)
- 2190-6009
- OpenAlex
- W3207613937
- Cited by
- 92
- References
- 27
- FWCI
- 6.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti‐diabetic drugs and sarcopenia: emerging links, mechanistic insights, and clinical implications. https://app.cochat.ai/papers/10.1002/jcsm.12838
- The paper
- Zhang, X., Zhao, Y., Chen, S., & Shao, H. (2021). Anti‐diabetic drugs and sarcopenia: emerging links, mechanistic insights, and clinical implications. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.12838
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.